Peroxisome proliferator-activated receptor alpha L162V polymorphism in nonalcoholic steatohepatitis and genotype 1 hepatitis C virus-related liver steatosis

Verdi, H; Koytak, ES; Onder, Fatih; Cinar, K; Idilman, R; Erden, E; Bozdayi, AM; Yurdaydin, M; Uzunalimoglu, D; Bozkaya, H

doi:10.2310/6650.2005.53706

Peroxisome proliferator-activated receptor alpha L162V polymorphism in nonalcoholic steatohepatitis and genotype 1 hepatitis C virus-related liver steatosis

Copy For Citation

Verdi H., Koytak E., Onder O. , Cinar K., Idilman R., Erden E., ...More

JOURNAL OF INVESTIGATIVE MEDICINE, vol.53, no.7, pp.353-359, 2005 (Journal Indexed in SCI)

Publication Type: Article / Article
Volume: 53 Issue: 7
Publication Date: 2005
Doi Number: 10.2310/6650.2005.53706
Title of Journal : JOURNAL OF INVESTIGATIVE MEDICINE
Page Numbers: pp.353-359

Abstract

Background: Peroxisome proliferator-activated receptor a (PPAR alpha) plays important roles in lipid metabolism. A recently discovered L162V polymorphism of the PPARa gene is associated with enhanced transcriptional activity. In this study, the frequency of L162V was investigated in nonalcoholic steatohepatitis (NASH) and genotype 1 hepatitis C virus (HCV)-related liver steatosis.